ArticleBMC cancer2025
Identifying NDUFB2 as a prognostic biomarker for glioblastoma through an exploratory analysis of an anesthesia-related gene signature.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundGlioblastoma (GBM) is the most aggressive primary brain tumor with poor prognosis despite multimodal therapy. Understanding the molecular and genetic characteristics of GBM and the influence of anesthesia drugs on tumor behavior is crucial for developing new therapeutic strategies.
methodsWe analyzed RNA-seq data from The Cancer Genome Atlas (TCGA)-GBM cohort and a Gene Expression Omnibus (GEO) dataset (GSE179004) of GBM samples treated with propofol and sevoflurane. Differential expression analysis identified anesthesia-related genes (ARGs), and their prognostic relevance was assessed using Cox regression. Consensus clustering stratified GBM patients into subgroups with distinct survival outcomes, immune cell infiltration, and pathway activities. An ARGs-based prognostic model was developed using Lasso-Cox regression and validated across cohorts. The hub gene NDUFB2 was identified and validated using single-cell sequencing, drug sensitivity assessment, and spatial transcriptome analysis. NDUFB2 expression levels were experimentally verified in our GBM samples.
resultsARGs were significantly differentially expressed between GBM and normal tissues, with NDUFB2 identified as a hub gene associated with poor prognosis. Consensus clustering divided GBM patients into two subgroups with significant survival differences. An 11-ARGs-based prognostic model was established, demonstrating strong correlation with overall survival. NDUFB2 was predominantly expressed in malignant cells and associated with decreased survival and drug sensitivity.
conclusionsOur study, based on an initial exploratory analysis of anesthesia-related genes (ARGs), highlights their potential prognostic significance in GBM. We propose NDUFB2 as a robust biomarker for prognosis and therapeutic response, supported by extensive validation. These findings offer insights into the molecular classification of GBM and suggest a possible impact of anesthesia drugs on tumor progression, warranting further validation in larger cohorts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.